<DOC>
	<DOCNO>NCT02228616</DOCNO>
	<brief_summary>The purpose study evaluate efficacy prucalopride 2 mg , give orally daily 12 week , combination PEG lactulose , treatment woman Chronic Constipation ( CC ) laxatives fail provide adequate relief , measure percentage subject weekly average increase 1 spontaneous complete bowel movement ( SCBMs ) ( responder ) 12-week treatment phase compare baseline .</brief_summary>
	<brief_title>Efficacy Safety Prucalopride Combination With Polyethylene Glycol Lactulose Women With Chronic Constipation</brief_title>
	<detailed_description>This multicenter , open-labeled , single-arm , interventional study evaluate efficacy safety prucalopride real clinical practice . It consist 2 phase : 1-week run-in phase , 12 week , open-label treatment phase . Study population woman CC treat laxative fail obtain adequate relief within precede 6 month . Patients meet inclusive without exclusive criterion enrol study sign Informed Consent Form . They instruct change diet , lifestyle study . At first week study , subject continue PEG lactulose treatment , allow use laxatives drug CC . Subjects require maintain write stool diary well use PEG lactulose . Any drug affect colonic motility prohibit study . Following run-in phase , subject enter 12-week open-label treatment phase . During treatment phase , subject treat 12 week prucalopride 2 mg , give orally daily without breakfast morning . Subjects require continue PEG lactulose treatment dosage run-in period . If necessary , due intolerable side effect ( ie , severe diarrhea , ) , dosage decrement PEG lactulose treatment may make time subject could discontinue PEG lactulose treatment , base investigator 's judgement . Subjects record study drug laxative medication dose information information relate BMs daily diary throughout study . PAC-SYM PAC QOL questionnaire complete Weeks 0 , 4 , 12 . Subject safety monitor throughout study .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Lactulose</mesh_term>
	<criteria>Inclusion criterion screen phase : Women age 18 65 year , inclusive History chronic constipation ( CC ) : The subject report , weekly average 2 few spontaneous bowel movement ( SBMs ) 1 follow within precede 3 month screen visit , symptom onset 6 month screen visit : 1. hard ( little ball ) and/or hard stool 25 % BMs ; 2. sensation incomplete evacuation 25 % BMs ; 3. strain defecation 25 % BMs ; 4. sensation norectal obstruction blockade 25 % BMs ; 5 . A need digital manipulation facilitate evacuation 25 % BMs Subjects use PEG lactulose treatment 1 week screen Be nonpregnant , nonlactating woman . Sexually active woman must post menopausal , surgically sterile , practice effective method birth control ( eg , prescription oral contraceptive , contraceptive injection , intrauterine device , double barrier method , contraceptive patch , male partner sterilization ) entry throughout study . Women must negative serum betahuman chorionic gonadotropin pregnancy test screen negative urine pregnancy test immediately prior study drug titration Inclusion Criteria treatment phase : At Visit 2 ( Week 0 ) , diary Week 1 collect examine presence chronic constipation . The subject consider eligible treatment phase follow criterion meet : Number SCBMs 2 few runin phase ( 1 week ) Subject NO SBMs runin phase consider constipated Potential subject meet follow criterion exclude participate study Subjects constipation think druginduced Subjects suffer secondary cause CC Use intent use disallow medication influence bowel habit study ( ie , anticholinergic [ include antihistamine ] , opioids , spasmolytic , prokinetics , tricyclic antidepressant ) Subjects severe clinically uncontrolled cardiovascular , liver , lung disease , neurologic psychiatric disorder ( include active alcohol drug abuse ) , cancer acquire immune deficiency syndrome ( AIDS ) , gastrointestinal endocrine disorder Subjects impair renal function , i.e. , serum creatinine &gt; 2 milligram/deciliter ( &gt; 180 micromole/Liter ) Subjects clinically significant abnormality hematology , urinalysis , blood chemistry Known allergy , hypersensitivity , intolerance prucalopride excipients Women pregnant breastfeed</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Constipation</keyword>
	<keyword>Chronic constipation</keyword>
	<keyword>Prucalopride</keyword>
	<keyword>Women</keyword>
</DOC>